Skip to main content
. 2022 Apr 9;107(2):458–473. doi: 10.1093/biolre/ioac070

Figure 6.

Figure 6

The effects of the type I receptor inhibitor SB431542 on the activin A-induced upregulation of HAS2 and versican in primary hGL cells. (A and B) Primary hGL cells were treated with Ctrl or 50 ng/mL activin A for 12 h, and the mRNA levels of HAS2 (A) and versican (B) were examined using RT-qPCR. (C and D) Primary hGL cells were treated with Ctrl or 50 ng/mL activin A for 12 h, and the protein levels of HAS2 (C) and versican (D) were examined using western blotting. (E and F) Primary hGL cells were pretreated with DMSO or SB431542 (10 μM) for 30 min and then the cells were treated with Ctrl or 50 ng/mL activin A for an additional 12 h. The mRNA levels of HAS2 (E) and versican (F) were examined using RT-qPCR. The results are expressed as the means ± SEM of at least three independent experiments. Student’s t-test was used to analyze two groups (*P < 0.05). One-way ANOVA was used to analyze multiple groups (values without a common letter were significantly different, P < 0.05).